Alfuzosin treatment benign prostatic hypertrophy BPH-ALF Group long-term efficacy safety alfuzosin selective alpha antagonist symptomatic patients benign prostatic hypertrophy BPH alfuzosin daily mg placebo months Obstructive irritative symptoms Boyarsky scale alfuzosin group placebo group patients alfuzosin group placebo group due efficacy vs prevalence spontaneous acute urine retention alfuzosin group vs months mean urinary flow rates residual volume alfuzosin group groups similar respect peak flow rate overall incidence adverse events similar groups withdrawal patients findings magnitude placebo response symptomatic patients BPH treatment alpha adrenergic antagonist drugs long-lasting improvement patients 